10-Q: Cooper Companies Q3 Earnings Mixed Amid Strong Vision Growth

The Cooper Companies reported mixed third-quarter results with strong CooperVision sales growth offset by a significant operating loss in CooperSurgical due to product line write-offs.

Summary

• Net sales for the three months ended July 31, 2025, increased by 5.7% to $1,060.3 million from $1,002.8 million in the prior year.
• Net income for the three months decreased by 6.2% to $98.3 million, down from $104.7 million in the same period last year.
• Diluted earnings per share for the three months decreased to $0.49 from $0.52 year-over-year.
• For the nine months ended July 31, 2025, net sales grew 5.2% to $3,027.3 million, and net income increased 5.6% to $290.3 million.
• CooperVision segment net sales rose 6% to $718.4 million for the quarter, driven by toric and multifocal lenses (+10%) and sphere, other lenses (+3%).
• CooperSurgical segment net sales increased 4% to $341.9 million for the quarter, with fertility sales up 6% and office and surgical sales up 3% due to acquisitions.
• Consolidated gross margin for the three months decreased to 65% from 66% due to inventory write-offs related to a product line exit.
• CooperSurgical's operating income for the quarter was a loss of $4.2 million, a significant decline from a $41.3 million profit in the prior year, primarily due to inventory and long-lived asset write-offs.
• Cash provided by operating activities for the nine months increased by 24.2% to $548.2 million.
• The company repurchased 0.7 million shares for $52.2 million during the quarter, with $163.6 million remaining authorized under the share repurchase program.
• A material weakness in IT general controls for U.S. operations within the CooperSurgical segment was identified, rendering disclosure controls and procedures ineffective as of July 31, 2025.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While CooperVision shows strong growth and overall nine-month financials are positive, the significant operating loss in CooperSurgical due to write-offs and the identified material weakness in internal controls are notable concerns. The cessation of dividends also impacts investor sentiment. The improved operating cash flow and share repurchases are positive, but the immediate quarterly performance is mixed.

Positives

• Strong net sales growth for both the three months (+5.7%) and nine months (+5.2%) ended July 31, 2025.
• CooperVision segment demonstrated robust performance with 6% net sales growth for the quarter and 17% increase in operating income, driven by successful Biofinity and MyDay products.
• Cash provided by operating activities significantly increased by $107.0 million (24.2%) for the nine months ended July 31, 2025, indicating improved operational cash generation.
• Interest expense decreased by 11% for the quarter and 13% for the nine months, primarily due to lower interest rates and reduced average debt balances.
• The company remains in compliance with all debt covenants, indicating sound financial management of its credit facilities.
• Share repurchases totaling $52.2 million during the quarter and $92.8 million year-to-date demonstrate a commitment to returning value to shareholders.

Negatives

• Net income for the three months ended July 31, 2025, decreased by 6.2% to $98.3 million, and diluted EPS fell by 5.8% to $0.49.
• CooperSurgical segment reported an operating loss of $4.2 million for the quarter, a substantial decline from a $41.3 million profit in the prior year, primarily due to inventory and long-lived asset write-offs from a product line exit.
• Consolidated gross margin for the three months decreased by one percentage point to 65%, impacted by the aforementioned inventory write-offs.
• Selling, general and administrative (SGA) expenses increased across both segments and corporate, with CooperSurgical's SGA up 19% for the quarter due to write-offs and increased selling activities.
• The company's Board of Directors decided to end the declaration of a semiannual dividend in December 2023, which may impact income-focused investors.
• A material weakness in IT general controls for U.S. operations within the CooperSurgical segment was identified, leading to a conclusion that disclosure controls and procedures are not effective as of July 31, 2025.

Risks

• Adverse changes in global or regional general business, political, and economic conditions, including uncertainty, instability, natural disasters, pandemic conditions, inflation, and foreign exchange rate fluctuations.
• Impact of international conflicts and global responses on the economy, financial markets, energy markets, currency rates, and product supply.
• Challenges of managing substantial and expanding international operations and complying with diverse legal, compliance, and regulatory requirements.
• The actual imposition or threats of tariffs, customs duties, trade protection measures, and other trade barriers.
• Increased interest expense from existing and future variable rate indebtedness due to rate increases.
• Changes in tax laws, examinations by tax authorities, and shifts in the geographic composition of income.
• Acquisition-related adverse effects, including failure to achieve anticipated benefits, integration delays, regulatory approval issues, and increased leverage.
• Compliance costs and potential liability related to U.S. and foreign privacy and security laws (e.g., HIPAA, CCPA, GDPR), including data security breaches.
• Major disruptions in manufacturing, accounting, financial reporting, R&D, distribution facilities, or raw material supply chain due to integration challenges, disasters, cybersecurity incidents, or third-party vendor failures.
• Market consolidation of large customers globally, leading to a higher concentration of business from fewer customers.
• Disruptions in supplies of raw materials, particularly components for silicone hydrogel lenses.
• New U.S. and foreign government laws and regulations, and changes in existing laws, affecting the healthcare, contact lens, medical device, or pharmaceutical industries (e.g., EU MDR/IVDR).
• Legal costs, insurance expenses, settlement costs, and the risk of adverse decisions or injunctions related to product liability, patent infringement, or other litigation.
• Limitations on sales following product introductions due to poor market acceptance.
• New competitors, product innovations, or technologies, including advances by competitors and their expansion through acquisitions.
• Reduced sales, loss of customers, reputational harm, and costs from product recalls and warning letters.
• Failure to receive, or delays in receiving, regulatory approvals or certifications for products.
• Failure of customers and end users to obtain adequate coverage and reimbursement from third-party payers for products and services.
• The requirement to provide for a significant liability or to write off, or accelerate depreciation on, a significant asset, including goodwill, other intangible assets, and idle manufacturing facilities and equipment.
• Risks related to environmental laws and requirements, including evolving regulations regarding hazardous substances.
• Risks related to environmental, social, and corporate governance (ESG) issues, including regulatory and disclosure requirements, climate change, and sustainability.

Future Outlook

The company is optimistic about the long-term prospects for the worldwide contact lens and general healthcare markets, and the resilience and growth prospects for its businesses and products. CooperVision aims for greater worldwide market penetration with recently introduced products and continues to expand in existing and emerging markets, including through acquisitions, focusing on silicone hydrogel products and myopia management. CooperSurgical plans to maintain its market presence through technological and scientific advances, product quality, and strategic acquisitions in fertility and women's health. The company anticipates that current cash, cash equivalents, future operating cash flow, and available credit will be sufficient to meet anticipated cash needs for at least the next 12 months, with additional funds potentially sourced through further indebtedness or equity financings for strategic activities like acquisitions or share repurchases.

Management Comments

• We are optimistic about the long-term prospects for the worldwide contact lens and general health care markets, and the resilience of and growth prospects for our businesses and products.
• CooperVision is focused on greater worldwide market penetration using recently introduced products, and we continue to expand our presence in existing and emerging markets, including through acquisitions.
• Our ability to compete successfully with a full range of silicone hydrogel products is an important factor to achieving our desired future levels of sales growth and profitability.
• CooperSurgical has established its market presence and distribution system by developing products and acquiring companies, products and services that complement its business model.
• We are committed to ensuring that our internal control over financial reporting is designed and operating effectively.

Industry Context

The Cooper Companies operates in the growing global contact lens and women's healthcare/fertility markets. CooperVision's focus on silicone hydrogel lenses, particularly single-use modalities (clariti, MyDay, MyDay Energys), aligns with broader industry trends towards convenience and advanced materials. Its investment in myopia management (MiSight 1 day lens) positions it in a high-growth niche addressing a significant global health concern. CooperSurgical's strategy of acquiring specialized medical device and fertility companies (obp Surgical, sperm separation devices, Cook Medical assets) reflects a trend of consolidation and diversification within the women's health and fertility sectors, aiming to offer comprehensive solutions. The overall market is characterized by technological advancements and increasing demand for specialized healthcare solutions.

Comparison to Industry Standards

• CooperVision's 6% net sales growth in the contact lens market, particularly the 10% growth in toric and multifocal lenses, suggests strong performance relative to a mature but growing industry, where innovation in materials and designs (like silicone hydrogel) is key. Competitors like Alcon, Johnson & Johnson Vision, and Bausch + Lomb also focus on these segments, making CooperVision's growth indicative of market share gains.
• The significant operating loss in CooperSurgical due to product line write-offs is a notable deviation from typical industry performance, where medical device and fertility segments generally exhibit stable to growing profitability. While acquisitions can lead to restructuring costs, a 110% decline in operating income for the quarter highlights a specific operational challenge or strategic shift within this segment.
• The company's continued investment in R&D, with increases of 13% for CooperVision and 17% for CooperSurgical in the quarter, is consistent with industry standards for medical technology companies that rely on innovation to maintain competitive advantage and address evolving patient needs.

Corporate Governance

Legal Proceedings

• The Company is involved in various lawsuits, claims, and other legal matters arising in the ordinary course of business, including matters involving products, intellectual property, supplier relationships, distributors, competitor relationships, and employees. Management does not believe the ultimate resolution of these proceedings could have a material adverse effect on its financial condition or results of operations.

Stakeholder Impact

• **Shareholders:** Mixed impact due to strong CooperVision growth and share repurchases, but offset by CooperSurgical's operating loss, reduced quarterly net income/EPS, and the cessation of semiannual dividends. The material weakness in internal controls could also be a concern.
• **Employees:** Remediation efforts for the IT general controls material weakness include developing skill sets and additional training programs, which could benefit employees in the affected areas.
• **Customers:** Continued focus on new product introductions (e.g., MiSight 1 day lens, silicone hydrogel products) and acquisitions in women's health and fertility aim to enhance product offerings and services.
• **Creditors:** The company remains in compliance with all debt covenants, and management believes current liquidity and future cash flows are sufficient to meet anticipated cash needs, indicating a stable credit profile.

Next Steps

• Continue remediation efforts for the material weakness in IT general controls for the CooperSurgical segment, focusing on enhancing risk assessment, employee training, and improving change management and user access controls.
• Make the second $50.0 million installment payment for the Cook Medical acquisition on November 1, 2025.
• Evaluate the impact and prepare for the adoption of new accounting standards: ASU 2025-05 (Credit Losses) effective for fiscal years beginning after December 15, 2025; ASU 2024-03 (Expense Disaggregation Disclosures) effective for fiscal years beginning after December 15, 2026; ASU 2023-09 (Income Tax Disclosures) expected to be adopted for fiscal year ending October 31, 2026; and ASU 2023-07 (Segment Reporting) effective from fiscal year ended October 31, 2025, and interim periods within fiscal years beginning from November 1, 2025.
• Continue to pursue worldwide market penetration for CooperVision, especially with new products and in emerging markets, including through acquisitions.
• Continue to develop and acquire products and services for CooperSurgical to complement its business model in fertility and women's health.

Key Dates

Recommendation

The Cooper Companies presents a mixed financial picture. While CooperVision shows robust growth and the company's overall nine-month performance is positive with strong operating cash flow, the significant operating loss in CooperSurgical due to product line write-offs and the identified material weakness in internal controls are notable concerns. The cessation of dividends removes a key return for some investors. The company's strategic acquisitions and R&D investments are positive long-term drivers, but the short-term headwinds and governance issues warrant a 'hold' recommendation until the CooperSurgical segment stabilizes and the internal control weakness is fully remediated. Investors should monitor the effectiveness of remediation efforts and CooperSurgical's future profitability.

Keywords

Contact Lenses, Women's Health, Fertility, Medical Devices, CooperVision, CooperSurgical, 10-Q, Quarterly Report, Financial Results, SEC Filing, Healthcare, Ophthalmology, Gynecology, Myopia Management, Silicone Hydrogel, Share Repurchase, Internal Controls